Status:

COMPLETED

Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Parkinson Disease

Eligibility:

All Genders

Brief Summary

Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the s...

Eligibility Criteria

Inclusion

  • Patients with Idiopathic Parkinson's disease who are planned to undergo a switch from another dopamine agonist to Sifrol®

Exclusion

  • Neurologists and psychiatrists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®

Key Trial Info

Start Date :

February 1 2002

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

1216 Patients enrolled

Trial Details

Trial ID

NCT02231255

Start Date

February 1 2002

Last Update

September 17 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease | DecenTrialz